Geminor M 3mg/500mg Tablet is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to enhanced glucose uptake and utilization. The synergistic action of these two agents provides effective glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Geminor M is prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is essential to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, a potential side effect due to increased insulin secretion. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, predominantly attributed to Metformin. Contraindications include renal impairment, hepatic dysfunction, and conditions predisposing to lactic acidosis. Prior to initiating therapy, thorough patient evaluation and periodic monitoring of renal function, liver enzymes, and hematologic parameters are recommended to ensure safety and efficacy. Geminor M should be used under medical supervision with adherence to prescribed dosing schedules.